LONG BEACH, Calif. / May 16, 2023 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) (“Molina”) today announced that Jim Woys and Mark Keim have each been promoted to the position of senior executive vice president, effective May 15th. With this promotion, Woys also assumes the role of chief operating officer. Keim will continue as chief financial officer with expanded operational and growth-related responsibilities.
Woys has served as Molina’s executive vice president – health plan services, since May 2018. Keim had served as Molina’s executive vice president – transformation, since January 2018, and became chief financial officer in February 2021.
"Jim and Mark have been instrumental leaders of Molina’s growth and performance over the past five years," said Joe Zubretsky, president and chief executive officer of Molina. "I look forward to working with them and our deep and talented leadership team to drive the next wave of value creation for all of our stakeholders."
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 125), provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. Molina Healthcare served approximately 5.3 million members as of March 31, 2023, located across 19 states. For more information about Molina Healthcare, please visit molinahealthcare.com.
Last Trade: | US$310.80 |
Daily Change: | -2.09 -0.67 |
Daily Volume: | 220,612 |
Market Cap: | US$17.780B |
November 18, 2024 October 23, 2024 October 16, 2024 July 23, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load